Background: Hyperglycemia is common during treatment for pediatric acute lymphoblastic leukemia (ALL). Several risk factors have been proposed, but emergence of new evidence suggests conflicting results. In view of ethnic differences in the propensity for diabetes, this study aims to delineate the characteristics of pediatric patients at risk for hyperglycemia during chemotherapy in Taiwan. Methods: This retrospective study involved chart review of consecutive patients younger than 18 years with diagnosis of ALL in a medical center in Taiwan from 1997 to 2008. Hyperglycemia was defined by random plasma glucose levels !200 mg/dL or fasting glucose levels !126 mg/dL in at least two separate samplings. Risk factors for hyperglycemia were described with crude and adjusted odds ratios (OR) with 95% confidence intervals (CI) in the univariate and multivariate regression analysis. Results: A total of 133 patients were included for analysis. Overall, 22 patients (16.5%) experienced hyperglycemia during ALL treatment. Most hyperglycemic episodes occurred within the first 8 days after prednisolone use. Age older than 10 years was the most important predictor of hyperglycemia (adjusted OR Z 10.88, 95% CI 2.40e49.37). Patients with fasting glucose concentration !100 mg/dL were also 5.7-fold (95% CI 1.63e19.93) more likely to develop hyperglycemia, whereas the predictive significance of obesity was attenuated after adjustment. Conclusion: Assessment of glucose concentration should be vigilant in the 1 st week after prednisolone use during ALL treatment. Clinicians should be alert to the patient at risk of hyperglycemia, particularly obese adolescents with disarranged glucose homeostasis.
Introduction
Overweight and obesity in childhood and adolescence have been implicated in association with various adverse health consequences. 1, 2 The rising prevalence of obesity among children is an emerging problem of public health worldwide and Taiwan is no exception. 3 A particular concern for obesity in childhood is given to the increased likelihood of deregulation in glucose metabolism during and even after treatment for acute lymphoblastic leukemia (ALL). 4, 5 Hyperglycemia is a common occurrence in pediatric patients during induction chemotherapy of ALL. 6e8 The potential causes may include beta cell dysfunction caused by chemotherapeutic drugs such as L-asparaginase, increased insulin resistance and hepatic gluconeogenesis induced by corticosteroids, or synergistic effects of these medications, given that these pharmacological agents are usually combined during initial induction therapy. 4, 5 The spectrum of hyperglycemia can range widely from transient isolated episodes to severe life-threatening complications such as diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar syndrome. 9e11 Transient hyperglycemia developed during this period largely resolves as the chemotherapy is discontinued. 12 However, affected children may need longer hospitalization and delay in chemotherapy; they may experience increased infective incidence and may even have poorer survival outcomes. 13, 14 Recognizable risk factors for treatment-related hyperglycemia have been studied among children who are characterized by Down syndrome, older than 10 years of age, obese at the start of chemotherapy, classified in the higher risk group for ALL, and using native L-asparaginase. 5e7, 12, 13 However, several conflicting results in more recent studies have indicated the absence of significant associations between weight status and hyperglycemic episodes. 8,14e16 Given the rising rate of obesity and overweight among Taiwanese children, in the past 10 years, those who receive treatment for leukemia may be at a higher risk for secondary hyperglycemia. Because ALL treatment protocol evolves over time, the side effects of therapy should be continually reevaluated. Few published data have referred to the epidemiology of treatment-related hyperglycemia in Asian pediatric patients with ALL. 17 The purpose of the current study is to evaluate the incidence and risk factors of hyperglycemia during the treatment for leukemia among Taiwanese children.
Materials and methods
This is a retrospective study involving a cohort of consecutive patients, age younger than 18 years, in whom ALL was diagnosed and who were admitted to National Cheng Kung University Hospital, Tainan, Taiwan, between January 1997 and December 2008. The hospital is a tertiary medical center for children with pediatric cancer diseases from Tainan and neighboring municipalities.
Variables and measures
Using the body mass index (BMI) growth chart among normative Taiwanese children beginning at 2 years of age, we excluded patients who were younger than 2 years. 18 Children with previously diagnosed diabetes mellitus (DM) or who were treated with glucocorticoids were also excluded. Medical records were reviewed to obtain relevant clinical data, including demographic information, such as age at diagnosis, sex, weight, height, and family history of diabetes as well as clinical parameters, such as initial white blood cell count (WBC), initial C-reactive protein (CRP) level, initial fasting glucose level, immunotyping of leukemic cells, risk classification, and outcome variables, such as leukemic relapse, death, and infective complications. Our standard practice is to admit all patients with fever or suspected vesicular skin lesions and to treat them with empirical antibiotics or antiviral agents accordingly. Infective complications were thus defined as occurrences of aforementioned episodes at any time of the entire chemotherapy regardless of clinical severity or identifiable pathogens after investigation. Family history of diabetes was defined by the presence of diabetes mellitus in patients' first-or second-degree relatives. Hyperglycemia was defined as at least two separate random plasma glucose levels !200 mg/dL or fasting glucose levels !126 mg/dL according to the published guidelines for childhood diabetes. 19 Fasting glucose concentrations were checked before chemotherapy and routinely as indicated during hospitalization. Moreover, patients with hyperglycemia or glucosuria received more intense monitoring for plasma glucose levels. BMI was calculated by dividing weight in kilograms by height in square meters. We determined the weight status according to the gender and age-specific BMI charts using the Taiwan reference data. BMI from the 5 th percentile to less than the 85 th percentile was classified as "healthy weight"; BMI from the 85 th percentile to less than the 95 th percentile was classified as "overweight"; and BMI greater than the 95 th percentile was classified as "obesity". 18, 20 The 1 st day of treatment was designated when the use of steroids was started. The entire procedure was approved by the Institutional Review Board of National Cheng Kung University Hospital, Tainan, Taiwan.
Treatment regimens
All patients were treated according to the protocols of the Taiwan Pediatric Oncology Group (TPOG). Given that the study period spanned from 1997 to 2008, some modifications are worthy of mention in the TPOG protocols in 2002. Before 2002, patients in the standard-risk (SR) and high-risk (HR) groups received the treatment regimens of TPOG-ALL-93 SR/HR, and those with patients in the very-high-risk (VHR) groups received the treatment regimen of TPOG-ALL-97 VHR. After 2002, these protocols were merged as the TPOG-ALL-2002. In brief, patients in the SR group received a 5-week induction remission regimen that consisted of prednisolone, vincristine, and either epirubicin or L-asparaginase in the TPOG-ALL-93 SR/HR, whereas epirubicin was only used as the third chemotherapeutic drug in the TPOG-ALL-2002. In addition, an additional nine doses of L-asparaginase were concurrently administered in the remission induction treatment in the case of the HR patients. Although 300 mg/m 2 for SR patients and 600 mg/m 2 of etoposide for HR patients were given in the TPOG-ALL-93 SR/HR, this drug was no longer used in the TPOG-ALL-2002. The other major difference in induction therapy was prednisolone dosage, which was reduced from 60 mg/m 2 in the TPOG-ALL-93 SR/HR to 40 mg/m 2 in the TPOG-ALL-2002. After clinically complete remission was achieved, patients further received consolidation therapy that consisted of intermediate doses of methotrexate and mercaptopurine and subsequent maintenance treatment. A reinduction course was applied during the consolidation phase for standard-risk patients and during the maintenance phase for the HR patients. Instead, the VHR patients received a 6-week remission induction therapy of prednisolone, vincristine, idarubicin, and L-asparaginase, followed by a 4-week course of cyclophosphamide, cytarabine, and mercaptopurine. Although drugs used in the consolidation phase were identical to those used in the HR patients, a reinduction course ensued after the consolidation phase. The regimen used in the continuation phase was basically composed of four pairs of multiple drugs with a weekly rotation. All VHR patients received a triple intrathecal therapy. Detailed combinations for antileukemic medications can be obtained elsewhere. 21 
Statistical analysis
We compared demographic and clinical differences between patients with and without hyperglycemia during ALL treatment using a Student t test for continuous variables and a Chi-square test for categorical variables with p < 0.05 considered statistically significant. The odds ratios (OR) of probability of developing hyperglycemia in patients with certain characteristics were described. Those predictive parameters with statistical significance in the initial univariate analysis were further entered into multivariate logistic regression analysis to adjust for potential confounding variables. All statistical analyses were conducted using software SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
One hundred and seventy children were identified to have ALL in the medical charts, of whom only 133 (78.2%) were eligible for final analysis. Thirty-seven patients were excluded due to the following reasons: age < 2 years, against-advice discharge before induction chemotherapy, receipt of induction therapy in other hospitals, presence of hyperglycemia before induction chemotherapy, and mortality due to infection before or during induction chemotherapy. Table 1 summarizes the demographic and clinical characteristics of the study population. Median age at diagnosis was 5.9 years (range 2.1e17.9 years). Of the 133 patients, 76 (57.1%) were male; 27 (20.3%) were overweight or obese; and 13 (9.8%) had a family history of diabetes. Elevated fasting glucose at diagnosis was noted among 23 patients (17.3%). In terms of diagnosis and treatment, 112 patients (84.2%) patients received a diagnosis of B-cell lineage, and 84 (63.2%) received the TPOG-ALL-2002 regimen. There were 29 relapses (21.8%) during the time of the study, 24 (82.8%) of whom were refractory to the rescue therapy and consequently died of relapse.
Overall, hyperglycemia developed in 22 patients (16.5%); two of these patients had diabetic ketoacidosis and were treated with insulin. Among them, 19 hyperglycemic occurrences (86.4%) were noted within the first 8 days (median Z 5) after prednisolone use (Figure 1) . Another patient had a hyperglycemic episode on Day 23, and the other two patients had hyperglycemic episodes during the reinduction periods with dexamethasone use. Comparing those with and without hyperglycemia during treatment, frequency of hyperglycemic episodes differed in regard to age, BMI status, fasting glucose status, and risk group classification (Table 1 ). Immunotyping and protocols did not differentiate the occurrence of hyperglycemia. Patients with hyperglycemia had a lower number of infective episodes, which was 5.08 times as compared to 8.08 times in their counterparts. No obvious differences were seen in regard to the percentage of leukemia relapse. The chemotherapy was not changed for patients with hyperglycemia, as follow-up serum glucose levels gradually normalized, and the use of insulin could be successfully tapered for those with diabetic ketoacidosis. None of them had persistently elevated glucose levels after discontinuation of chemotherapy.
In the initial univariate analysis, hyperglycemia was 18.21 times more likely to develop in patients older than 10 years than in those younger than 10 years (Table 2) . Because patients older than 10 years should receive at least HR chemotherapy according to the TPOG risk classification system, we excluded SR patients from a subgroup analysis showing that patients older than 10 years still had a higher rate (18/39) of hyperglycemic occurrence than their younger peers (2/44) (F Z 19.57, p < 0.001). After adjusting for other possible covariates, age remained the strongest predictive factor for hyperglycemia among ALL patients (adjusted OR Z 10.88, 95% CI 2.4e49.37). Impaired fasting glucose at the time of diagnosis was also associated with hyperglycemia during chemotherapy (crude OR Z 8.25, 95% CI 2.95e23.07; adjusted OR Z 5.7, 95% CI 1.63e19.93). In addition, the increase in likelihood of hyperglycemia among patients who were obese (crude OR Z 4.38, 95% CI 1.35e14.2) and classified into high groups (crude OR Z 10.76, 95% CI 2.26e51.12), compared to the standard risk group as a reference, was diminished after multivariate adjustment.
Discussion
In our study, hyperglycemia was found to be a common occurrence during chemotherapy among Taiwanese pediatric patients. The prevalence was 16.5%, similar to that found in previous pediatric research. Pui and colleagues reported that 9.7% of patients experienced hyperglycemia during induction therapy in the early 1980s. 12 The following surveys estimated slightly increased rates in the range of 10e20%.
6e9 In order to identify the peak of hyperglycemic occurrence, we specifically looked at the timing in relationship to phases of treatment and the use of chemotherapy. As the TPOG-ALL protocol described, the start of chemotherapy is usually concomitant with the use of steroids. 21 However, this protocol is sometimes subject to changes in practice, so chemotherapeutic agents may actually begin several days after administration of steroids. We found that hyperglycemia occurred most often within the 1 st week after prednisolone use. The second peak of occurrence was within the stretch of the reinduction phase, which is thought to be associated with dexamethasone use. Interestingly, no patients with hyperglycemia during the induction phase developed another hyperglycemic episode in the following reinduction phases. This finding may support Sonabend et al's 13 research showing a higher rate of hyperglycemia in patients receiving prednisolone than counterparts receiving dexamethasone. Our retrospective study was not able to evaluate the aforementioned observation with head-to-head comparison. More clinical observations or pooled data may be needed to compare hyperglycemic effects of different corticosteroids in use. Previous studies have been supportive of a positive association between the occurrence of hyperglycemia and the use of chemotherapeutic agents, particularly L-asparaginase. 6, 12 Corticosteroids are commonly coadministered with L-asparaginase in chemotherapy for ALL, thus making it difficult to attribute cause of hyperglycemia to any single medication use. None of the hyperglycemic patients had concurrent hyperlipidemia or pancreatitis, which is even rarer (6e8%) in incidence and may cause permanent DM. 22, 23 Our findings would suggest that steroids are the main culprit leading to hyperglycemia by interacting with pubertal hormones, adiposity, and other medications used in the treatment. Meanwhile, leukemic cells themselves may also alter the metabolism of adipose cytokines and induce systemic inflammatory processes. 24 Together, these predisposing factors may further result in redistribution of adipose tissue and derangement of glucose regulation. 25, 26 Age was shown to be the most important contributor to hyperglycemia during ALL treatment in the analysis. Nearly 40% of patients older than 10 years developed hyperglycemia as opposed to only 3.2% of those younger than 10 years. Such a striking increase in the prevalence of hyperglycemia during adolescence has also been noted in previous studies conducted in USA and Canada. 6e9, 12 This may reflect rising insulin resistance under the influence of sex hormones along with pubertal progression. 27 The magnitude of insulin resistance can interact with and be further exaggerated by adiposity gained during the critical period of physical transition. As predicted, BMI status was also significantly related to the occurrence of hyperglycemia in the univariate analysis. Obesity is the major and most common cause of insulin resistance in the pediatric age group because excess adiposity, especially visceral adiposity, is considered to be a major risk factor for development of impaired glucose metabolism and metabolic syndrome in youth. 28, 29 Extending previous knowledge and measuring the effect of glucose metabolism among pediatric ALL patients, we added fasting glucose in the analysis model. Patients with elevated fasting glucose were found to be approximately five times more likely to have hyperglycemia during chemotherapy even after multivariate adjustment. In our analysis, we hypothesized that fasting glucose concentration could possibly mediate the effect of obesity on subsequent occurrences of hyperglycemia. Fasting glucose level is an essential laboratory marker of glucose tolerance. 30 Impaired glucose tolerance at the time of diagnosis may put affected patients at a greater risk for diabetes, and thus meticulous monitoring of glucose levels in subsequent management is warranted. 31 Direct measurement of insulin secretion was, however, not conducted in this retrospective study. Although the magnitude of insulin resistance could be assessed more accurately by an oral glucose tolerance test, its correlation with occurrence of hyperglycemia during treatment has not been verified and requires further investigation. Contrary to previous research, 9,13 patients without hyperglycemia seemed to have more infective episodes in our cohort. One possible reason may be that older patients are likely to develop hyperglycemia due to insulin resistance but are usually more immune to common infective diseases. In addition, younger patients are more likely to have contact with sick children in school and to exhibit severe clinical presentations that require hospitalization because of immune immaturity. As such, the relationship between infective outcomes and occurrences of hyperglycemia during leukemic treatment could be largely confounded by patient age. Also worthy of attention is that our operative symptom-based definition of infection, which is symptombased, may not truly reflect the cause and severity of infective episodes. Fever inherent to leukemia itself is sometimes indistinguishable from infection without an identifiable pathogen. Interpretation of the difference in the number of infections between patients with and without hyperglycemia should be made with due caution. A larger sample size with age-matched comparison is needed to further explore the aforementioned relationship.
The current retrospective study has some limitations that need be addressed along with its findings. First, the laboratory data were retrieved from medical charts. Although all patients received regular morning glucose assessments at least twice per week in the routine clinical care of induction chemotherapy, follow-up blood samplings for glucose concentration were only assigned on the basis of clinical symptoms and signs of hyperglycemia rather than at protocol-based time points. Exact time of onset may have therefore not been accurately recorded. Second, previous studies have involved postprandial glucose measurements in the diagnosis of hyperglycemia. We did not monitor postprandial glucose levels on a regular basis. As a result, asymptomatic postprandial hyperglycemic events were likely to be underreported in our cohort. A prospective standardized protocol with uniform time points at the measurement of serum glucose concentration would be needed to evaluate the evolution in glucose metabolism during chemotherapy. In addition, variations in clinical care exist among different hospitals and may alter the clinical outcomes of hyperglycemia. A larger registry involving multicenter pediatric patients with ALL may provide more solid evidence of the occurrence of hyperglycemia and associated clinical effects in the Taiwanese population.
In conclusion, our data have provided an overview of glycemic complications among patients treated with TPOG protocols. Assessment of glucose concentration should be performed with vigilance in pediatric patients receiving chemotherapy for leukemia especially within the 1 st week after prednisolone use, notably in obese adolescents. The strength of our study is it showed that fasting glucose could add predictive value to subsequent occurrence of hyperglycemia during chemotherapy. Based on this finding, we could better stratify ALL patients against risks for hyperglycemia and take preemptive actions to control glucose levels. The presence of hyperglycemia is usually transient with gradual resolution and thus may not necessarily warrant change of the treatment protocol. Although no differences in terms of leukemia relapse and infection occurrence were observed between patients with and without hyperglycemia, medication-induced diabetes during ALL therapy was recently shown to predict the development of metabolic derangements in this population in the long term. 32 The implications of these findings are twofold. With advancement of antileukemic therapy, continuous care and followup of metabolic consequences are recommended for survivors. Second, identifying the presence of factors predicting hyperglycemia (older age, abnormal glucose level at baseline, and possibly abnormal BMI) may lead to the early implementation of lifestyle changes; for example; during the induction-remission therapy. Whether these early lifestyle modifications could benefit the patients at risk for transient or long-term impaired glucose homeostasis will require further investigation.
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